The law firm of Lieff Cabraser Heimann & Bernstein, LLP announces that class action lawsuits have been brought on behalf of purchasers of the common stock of Beckman Coulter, Inc. between July 31, 2009 and July 22, 2010, inclusive (the "Class Period").

If you purchased Beckman common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than November 2, 2010. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in this action will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in this action.

Beckman shareholders that wish to learn more about this action and how to seek appointment as lead plaintiff should visit Lieff Cabraser's website at http://lieffcabraser.com/cases.php?CaseID=346 or contact attorney Sharon Lee toll free at (800) 541-7358.

Background on Beckman Coulter Securities Class Litigation

The actions, pending in the United States District Court for the Central District of California, were brought against Beckman and certain of its officers and directors for violations of the Securities Exchange Act of 1934. Beckman, headquartered in Brea, California, is a manufacturer and marketer of biomedical testing instrument systems, tests, and supplies.

The complaints in the above-mentioned actions allege that during the Class Period, defendants made materially false and misleading statements regarding Beckman's financial condition and business prospects. Specifically, defendants allegedly failed to disclose quality and compliance issues with respect to Beckman's troponin test, a critical care test used to aid in the diagnosis of cardiac events, and that the Company made certain modifications to the troponin test without obtaining required clearance from the Food and Drug Administration. In addition, defendants allegedly failed to disclose that Beckman failed to maintain proper controls with respect to product quality and regulatory compliance.

On July 22, 2010, Beckman reported disappointing results for the second quarter of 2010 and reduced its full-year 2010 guidance due in substantial part to troponin quality and compliance issues. On this news, Beckman's stock plummeted $12.64 per share, or more than 21 percent, to close at $47.26 per share on July 23, 2010.

About Lieff Cabraser

Lieff Cabraser Heimann & Bernstein, LLP, with offices in San Francisco, New York and Nashville, is a nationally recognized law firm committed to advancing the rights of investors and promoting corporate responsibility.

Since 2003, the National Law Journal has selected Lieff Cabraser as one of the top plaintiffs' law firms in the nation. In compiling the list, the National Law Journal examined recent verdicts and settlements in addition to overall track records. Lieff Cabraser is one of only two plaintiffs' law firms in the United States to receive this honor for the last seven consecutive years.

For more information about Lieff Cabraser and the firm's representation of investors, please visit http://www.lieffcabraser.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

SOURCE: Lieff Cabraser Heimann & Bernstein, LLP